Ascletis Pharma, Inc. (HK:1672) has released an update.
Ascletis Pharma Inc. reports promising interim results from a Phase II clinical trial of its drug ASC41, showing significant reductions in liver fat and improved liver enzymes in patients with metabolic dysfunction-associated steatohepatitis (MASH). The findings, presented at the EASL Congress 2024, highlight ASC41’s potential as a once-daily treatment to address this challenging liver condition. The data also suggest ASC41’s favorable safety profile and its differentiation from other treatments in the same drug class.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
